Bisphosphonate-related osteonecrosis of the mandible and maxilla: Clinical and imaging features

Journal of Computer Assisted Tomography

Volumn 33, Issue 3, 2009, Pages 449-454

  Gill, Sonia B ^a   Valencia, Maria P ^a   Sabino, Mary Lou C ^a   Heideman, Gregory M ^a   Michel, Michelle A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Bisphosphonates; Jaws; Mandible; Maxilla; Osteonecrosis

Indexed keywords

BONE; DIAGNOSIS;

BISPHOSPHONATES; BREAST CARCINOMAS; CLINICAL FEATURES; CONDITION; IMAGING FEATURES; JAW; MANDIBLE; MAXILLA; MULTIPLE MYELOMA; OSTEONECROSIS;

FRACTURE;

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BONE NECROSIS; BREAST CARCINOMA; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAW OSTEONECROSIS; LYMPHOMA; MALE; MULTIPLE MYELOMA; OSTEOMYELITIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; TOOTH EXTRACTION; CHEMICALLY INDUCED DISORDER; JAW DISEASE; MIDDLE AGED; RADIOGRAPHY;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MANDIBULAR DISEASES; MAXILLARY DISEASES; MIDDLE AGED; OSTEONECROSIS;

EID: 67649130075     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/RCT.0b013e318186b179     Document Type: Article

References (36)

1. Sparidans RW, Twiss IM, Talbot S. Bisphosphonates in bone diseases. Pharm World Sci. 1998;20:206-213.
2. Berenson J. Pamidronate in the treatment of osteolytic bone lesions in multiple myeloma patients-the American experience. Br J Clin Pract Suppl. 1996;87:5-7.
3. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastasis: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082-1090.
4. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-1117.
5. Magliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21:4253-4254.
6. Magliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. 2003:7(6);508-514.
7. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-534.
8. Magliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005;104:83-93.
9. Mortensen M, Lawson W, Montazem A. Osteonecrosis of the jaw associated with bisphosphonate use: presentation of seven cases and literature review. Laryngoscope. 2007;117(1):30-34.
10. Magopoulos C, Karakinaris G, Telioudis Z, et al. Osteonecrosis of the jaws due to bisphosphonate use: a review of 60 cases and treatment proposals. Am J of Otolaryngol. 2007;28(3):158-163.
11. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-1575.
12. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65(12):2397-2410.
13. Chiandussi S, Biasotto M, Dore F, et al. Clinical and diagnostic imaging in bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol. 2005;35:236-243.
14. Carneiro E, Vibhute P, Montazwm A, et al. Bisphosphonate-associated mandibular osteonecrosis. AJNR Am J Neuroradiol. 2006;27:1096-1097.
15. Garcia-Ferrer L, Bagan JV, Martinez-Sanjuan V, et al. MRI of mandibular osteonecrosis secondary to bisphosphonates. AJR Am J Roentgenol. 2008;190:949-955.
16. Phal PM, Myall RWT, Assael LA, et al. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol. 2007;28:1139-1145.
17. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97:2692.
18. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302:1055-1061.
19. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002;62:6538-6544.
20. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99-102.
21. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-376.
22. Bamias A, Kastritas E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580-8587.
23. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006;24:945-952.
24. Mavrokokki T, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415-423.
25. Hoff AO, Toth BB, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy [abstract]. J Clin Oncol. 2006;24(suppl):8528.
26. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastasis. Cancer. 2001;91:1191-1200.
27. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735-1744.
28. Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastasis. Clin Cancer Res. 2003;9:2394-2399.
29. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bispho-sphonates: evidence of increased risk after treatment with zoledronic acid. Hematologica. 2006;91:968-971.
30. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-center experience in 303 patients. Br J Haematol. 2006;134:620-623.
31. Marx RE. Oral and Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws: History, Etiology, Prevention, and Treatment. Chicago, IL: Quintessence Pub Co.; 2007:83.
32. Dodson TB, Raje NS, Caruso PA, et al. Case 9-2008: A 65-year-old woman with a nonhealing ulcer of the jaw. N Engl J Med. 2008;358:1283-1291.
33. Hansen T, Kunkel M, Weber A, et al. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006;35:155-160.
34. Hermans R. Imaging of mandibular osteoradionecrosis. Neuroimaging Clin N Am. 2003;13:597-604.
35. van der Waal RI, Buter J, van der Waal I. Oral metastasis: report of 24 cases. Br J Oral Maxillofac Surg. 2003;41:3-6.
36. Zarychanski R, Elphee E, Walton P, et al. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol. 2006;81:73-75.